Expression data from MCF7 tumor xenografts treated with either single agent BMS754807, or Tamoxifen or Letrozole alone; or Tamoxifen or Letrozole in combination with BMS754807 for 28 days

breast cancer. Combined IGF and estrogen-targeted therapy may improve the benefit of hormonal therapy alone. We employed a postmenopausal model of estrogen-dependent breast cancer in vitro and in vivo using the aromatase-expressing MCF-7/AC-1cells. Using this model, we investigated the anti-tumor effects of the dual IGF-1R/InsR tyrosine kinase inhibitor, BMS-754807 alone and in combination with letrozole or tamoxifen in vivo. We used microarrays to compare gene expression changes of MCF7 breast xenograft treated with either BMS754807, or Tamoxifen or Letrozole alone; or Tamoxifen or Letrozole in combination with BMS754807 for 28 days Breast xenograft MCF7 bearing mice treated with either BMS754807, or Tamoxifen or Letrozole alone; or Tamoxifen or Letrozole in combination with BMS754807 for 28 days. RNA were extracted from tumors and hybridizedon Affymetrix microarrays to compare gene expression changes

乳腺癌相关研究：联合胰岛素样生长因子（IGF）与雌激素靶向治疗或可提升单纯激素治疗的临床获益。本研究采用表达芳香化酶的MCF-7/AC-1细胞，构建了体外及体内的绝经后雌激素依赖性乳腺癌模型。依托该模型，我们在体内探究了双靶点胰岛素样生长因子1受体/胰岛素受体（IGF-1R/InsR）酪氨酸激酶抑制剂BMS-754807单药，以及其与来曲唑（letrozole）或他莫昔芬（tamoxifen）联合使用的抗肿瘤效应。我们通过基因微阵列技术，对比分析经以下方案处理28天的携带MCF-7乳腺癌异种移植瘤小鼠的基因表达变化：BMS-754807单药、他莫昔芬单药、来曲唑单药，或他莫昔芬/来曲唑联合BMS-754807。从肿瘤组织中提取核糖核酸（RNA），将其在Affymetrix基因微阵列上进行杂交，以对比基因表达差异。